InspireMD, an Israeli medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarction, announced positive three-year results from the extended follow up trial of patients suffering from acute coronary syndromes. Acute Myocardial Infarction is commonly known as a heart attack and results from the interruption of blood supply to the heart. According to the company, the results showed that the safety and efficacy of its MGuard stents were maintained at three years.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Inventor Of PDF, MP3, And ZIP Dies
March 30, 2023

Helmet Sends Magnetic Pulses To Treat Depression
March 30, 2023

AI To Monitor Vehicles At Mid-East Borders
March 30, 2023

Wireless Device Monitors Patients’ Vital Signs
March 29, 2023
Facebook comments